JP2015508903A - 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ - Google Patents

前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ Download PDF

Info

Publication number
JP2015508903A
JP2015508903A JP2014559890A JP2014559890A JP2015508903A JP 2015508903 A JP2015508903 A JP 2015508903A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2014559890 A JP2014559890 A JP 2014559890A JP 2015508903 A JP2015508903 A JP 2015508903A
Authority
JP
Japan
Prior art keywords
psma
imaging
patient
prostate cancer
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014559890A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015508903A5 (https=
Inventor
バンダー，ニール・エイチ
Original Assignee
コーネル ユニヴァーシティー
コーネル ユニヴァーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by コーネル ユニヴァーシティー, コーネル ユニヴァーシティー filed Critical コーネル ユニヴァーシティー
Publication of JP2015508903A publication Critical patent/JP2015508903A/ja
Publication of JP2015508903A5 publication Critical patent/JP2015508903A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2014559890A 2012-02-28 2013-02-27 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ Pending JP2015508903A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261604039P 2012-02-28 2012-02-28
US61/604,039 2012-02-28
PCT/US2013/000051 WO2013130177A1 (en) 2012-02-28 2013-02-27 Psma as a biomarker for androgen activity in prostate cancer

Publications (2)

Publication Number Publication Date
JP2015508903A true JP2015508903A (ja) 2015-03-23
JP2015508903A5 JP2015508903A5 (https=) 2016-04-14

Family

ID=49083148

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014559890A Pending JP2015508903A (ja) 2012-02-28 2013-02-27 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ

Country Status (6)

Country Link
US (1) US20130315830A1 (https=)
EP (1) EP2819704A4 (https=)
JP (1) JP2015508903A (https=)
CA (1) CA2865774A1 (https=)
HK (1) HK1202256A1 (https=)
WO (1) WO2013130177A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2904969C (en) 2013-03-13 2025-06-17 Imaginab, Inc. DIFFERENTIATION CLUSTER ANTIGEN-BINDING GENETIC CONSTRUCTIONS 8
WO2017027325A1 (en) 2015-08-07 2017-02-16 Imaginab, Inc. Antigen binding constructs to target molecules
MX2019008538A (es) 2017-01-20 2019-11-05 Juno Therapeutics Gmbh Conjugados de superficie celular y composiciones y métodos celulares relacionados.
EP3607319A1 (en) 2017-04-07 2020-02-12 Juno Therapeutics, Inc. Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
KR20210087938A (ko) * 2018-09-28 2021-07-13 이미지냅 인코포레이티드 Cd8 이미징 구조체 및 이의 사용 방법
US20240011996A1 (en) * 2020-11-24 2024-01-11 Korea Institute Of Science And Technology Biomarkers for diagnosing prostate cancer, combination thereof, and use thereof
EP4267969A4 (en) * 2020-12-22 2025-02-12 Mayo Foundation for Medical Education and Research METHODS AND MATERIALS FOR THE TREATMENT OF PROSTATE CANCER

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
JP2010540657A (ja) * 2007-10-03 2010-12-24 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
US20120009121A1 (en) * 2009-03-19 2012-01-12 The Johns Hopkins University Psma-targeting compounds and uses thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100047166A1 (en) * 2008-08-20 2010-02-25 Kanner Steven B Antibodies and related molecules that bind to 58p1d12 proteins
EP2419507A1 (en) * 2009-04-14 2012-02-22 Institut Gustave Roussy Prostate cancer cell lines and their use in screening method
WO2013126147A2 (en) * 2012-02-24 2013-08-29 Cornell University Elevated psma identifies lethal prostate cancers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005507857A (ja) * 2001-02-07 2005-03-24 ベズ イズレイル ディーコネス メディカル センター 改変ｐｓｍａリガンド及びそれに関する利用
JP2009530645A (ja) * 2006-03-21 2009-08-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｎ−カドヘリンおよびｌｙ６−ｅ：癌の診断および治療のための標的
JP2010540657A (ja) * 2007-10-03 2010-12-24 コーネル ユニヴァーシティー Ｐｓｍａ抗体を用いる増殖性障害の治療
US20100209343A1 (en) * 2009-02-17 2010-08-19 Cornell Research Foundation, Inc. Methods and kits for diagnosis of cancer and prediction of therapeutic value
US20120009121A1 (en) * 2009-03-19 2012-01-12 The Johns Hopkins University Psma-targeting compounds and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BELTRAN, H. ET AL.: "Molecular characterization of neuroendocrine Prostate cancer and identification of new Drug Targets", CANCER DISCOVERY, vol. 1, no. 6, JPN6017042419, 2011, pages 487 - 495, ISSN: 0003833599 *
EVANS, M. J. ET AL.: "Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical", PNAS, vol. 108, no. 23, JPN6017042418, 2011, pages 9578 - 9582, ISSN: 0003833598 *
TAI, S. ET AL.: "PC3 Is a Cell Line Characteristic of Prostatic Small Cell Carcinoma", THE PROSTATE, vol. 71, JPN6017042420, 2011, pages 1668 - 1679, ISSN: 0003833600 *

Also Published As

Publication number Publication date
EP2819704A1 (en) 2015-01-07
EP2819704A4 (en) 2015-10-21
HK1202256A1 (en) 2015-09-25
WO2013130177A1 (en) 2013-09-06
CA2865774A1 (en) 2013-09-06
US20130315830A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
Todo et al. A phase I/II study of triple-mutated oncolytic herpes virus G47∆ in patients with progressive glioblastoma
Chen et al. TGF-β1/IL-11/MEK/ERK signaling mediates senescence-associated pulmonary fibrosis in a stress-induced premature senescence model of Bmi-1 deficiency
US20250230259A1 (en) Androgen suppression, prostate-specific membrane antigen and the concept of conditionally enhanced vulnerability
Tao et al. Antagonism of EGFR and HER3 enhances the response to inhibitors of the PI3K-Akt pathway in triple-negative breast cancer
JP2015508903A (ja) 前立腺癌におけるアンドロゲン活性のバイオマーカーとしてのｐｓｍａ
Liu et al. Expression of antigen processing and presenting molecules in brain metastasis of breast cancer
D’Aguanno et al. Semaphorin 5A drives melanoma progression: role of Bcl-2, miR-204 and c-Myb
Suwa et al. SPINK1 as a plasma marker for tumor hypoxia and a therapeutic target for radiosensitization
Ghosh et al. Tumor tissue explant culture of patient-derived xenograft as potential prioritization tool for targeted therapy
Wang et al. A fully human insulin-like growth factor-I receptor antibody SCH 717454 (Robatumumab) has antitumor activity as a single agent and in combination with cytotoxics in pediatric tumor xenografts
Ke et al. Mechanical signal modulates prostate cancer immune escape by USP8-mediated ubiquitination-dependent degradation of PD-L1 and MHC-1
Liu et al. Identification of PHB2 as a potential biomarker of luminal a breast cancer cells using a cell-specific aptamer
Gayed et al. Digoxin inhibits blood vessel density and HIF‐1a expression in castration‐resistant C4‐2 xenograft prostate tumors
Liu et al. Slit2 and Robo1 expression as biomarkers for assessing prognosis in brain glioma patients
US20200246313A1 (en) Methods for diagnosing and treating prostate cancer
Chocarro-Calvo et al. Fatty acid uptake activates an AXL–CAV1–β-catenin axis to drive melanoma progression
Zhang et al. Secreted CLU is associated with the initiation of triple-negative breast cancer
Surve et al. Signaling events at TMEM doorways provide potential targets for inhibiting breast cancer dissemination
US20170336422A1 (en) Method for the detection of hormone sensitive disease progression
Gupta et al. Androgen receptor activation induces senescence in thyroid cancer cells. Cancers 2023 15 2198
Lin et al. Loss of estrogen receptor alpha promotes distant metastasis through epithelial-mesenchymal transition in luminal-type breast cancer
최연주 Prognostic and Therapeutic Implications of Nuclear Receptors and Glucose Metabolism in Sebaceous Carcinoma
Hojo et al. Insulin-like growth factor 2 mRNA-binding protein 3 (IMP3) expression in colorectal cancer with liver metastasis
Tian et al. Reptin regulates tumor cell growth and cisplatin resistance in osteosarcoma
Ortiz-Hernández et al. CYR61 promotes metastasis of prostate cancer cells through the p-AKT and AR signaling pathways

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20161221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170405

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170605

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180206

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180706